Accepted for/Published in: JMIR Research Protocols
Date Submitted: Jun 24, 2025
Date Accepted: Dec 29, 2025
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Jiedu Xiaozhen granules(JDXZ) for epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) mediated skin toxicity: A randomized controlled trial study protocol
ABSTRACT
Background:
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used in the treatment of non-small cell lung cancer (NSCLC) due to their precision, efficiency, and ease of use. However, skin rashes induced by EGFR-TKIs are the most common and earliest form of skin toxicity, often affecting the quality of life and treatment compliance of the patients and leading to early discontinuation of therapy. These skin reactions may even impact cancer outcomes. In clinical practice, Chinese medicine detoxification granules have shown effectiveness in relieving skin discomforts such as itching, pain, and burning caused by EGFR-TKIs therapy. A prior single-arm trial investigating the treatment of targeted drug-induced rashes demonstrated a sustained improvement in rash symptoms with an effective rate of 80.77% and was well tolerated by patients.
Objective:
Consequently, this randomized controlled trial (RCT) was designed to further evaluate the effectiveness and safety of Traditional Chinese Medicine (TCM) detoxification granules in the management of EGFR-TKIs mediated skin toxicity.
Methods:
This RCT will be conducted at Shanxi Provincial Hospital of TCM. A total of 100 patients with confirmed EGFR gene-mutated NSCLC who developed rashes after EGFR-TKIs treatment will be enrolled. Patients will be randomly assigned to either the JDXZ TCM group (Group J) or the urea ointment group (Group U). The primary outcome will be the severity of rash as assessed by NCI-CTCAE 5.0 grading. Secondary outcomes will include the WoMo score scale, numerical rating scale (NRS) scale, dermatology life quality index (DLQI) scale, EORTC QLQ C30 score, median progression-free survival (PFS), and changes in the levels of fibroblast growth factor 7 (FGF7) and hepatocyte growth factor (HGF) in blood. Adverse reactions will be recorded throughout the study. Data will be analyzed using the IBM SPSS 26.0 statistical software.
Results:
The results of this study may help develop an effective treatment for EGFR-TKIs mediated rashes.
Conclusions:
The findings will be published in academic journals upon the completion of the trial. Clinical Trial: This randomized controlled trial has been registered on the Chinese Clinical Trial Registry (ChiCTR2400086657).
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.